Global Estimates of Lives and Life-Years Saved by COVID-19 Vaccination During 2020-2024.

Publication date: Jul 03, 2025

Estimating global lives and life-years saved is important to put into perspective the benefits of COVID-19 vaccination. Prior studies have focused mainly on the pre-Omicron period or only on specific regions, and lack crucial life-year calculations and often depend on strong modeling assumptions with unaccounted uncertainty. To calculate the lives and life-years saved by COVID-19 vaccination worldwide from the onset of the vaccination campaigns and until October 1, 2024. This comparative effectiveness study considered different strata of the worldwide population according to age, community-dwelling and long-term care residence status, pre-Omicron and Omicron periods, and vaccination before and after a SARS-CoV-2 infection. Any COVID-19 vaccination in any schedule and number of doses. Death. In the main analysis, more than 2. 5 million deaths were averted (1 death averted per 5400 vaccine doses administered). Eighty-two percent were among people vaccinated before any infection, 57% were during the Omicron period, and 90% pertained to people 60 years or older. Sensitivity analyses suggested 1. 4 to 4. 0 million lives were saved. Some sensitivity analyses showed a preponderance of the benefit during the pre-Omicron period. An estimated 14. 8 million life-years were saved (1 life-year saved per 900 vaccine doses administered). The sensitivity range was 7. 4 to 23. 6 million life-years. Most life-years saved (76%) were among people 60 years or older, but long-term care residents contributed only 2% of the total. Children and adolescents (0. 01% of lives saved and 0. 1% of life-years saved) and young adults aged 20 through 29 years (0. 07% of lives saved and 0. 3% of life-years saved) had very small contributions to the total benefit. Estimates in this study are substantially more conservative than previous calculations focusing mostly on the first year of vaccination, but they still clearly demonstrate a major overall benefit from COVID-19 vaccination during the years 2020-2024. Most benefits in lives and life-years saved was secured for a portion of older persons, a minority of the global population.

Open Access PDF

Concepts Keywords
Deaths Adolescent
Effectiveness Adult
Global Aged
Vaccination Aged, 80 and over
Child
Child, Preschool
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Global Health
Humans
Infant
Life Expectancy
Male
Middle Aged
SARS-CoV-2
Vaccination
Young Adult

Semantics

Type Source Name
disease MESH COVID-19
disease MESH uncertainty
pathway REACTOME SARS-CoV-2 Infection
disease MESH Death
disease MESH infection
drug DRUGBANK Flunarizine
disease MESH reinfection
drug DRUGBANK Aspartame
disease MESH asymptomatic infection
disease IDO facility
disease MESH thrombosis
disease MESH myocarditis
drug DRUGBANK Dexamethasone
disease IDO quality
disease IDO pathogen
disease MESH measles
pathway KEGG Measles
disease MESH hepatitis
disease MESH yellow fever
disease MESH rubella
drug DRUGBANK Etoperidone
disease IDO country

Original Article

(Visited 2 times, 1 visits today)